...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: New RVX Tweet
6
Jul 28, 2020 03:46PM
12
Jul 28, 2020 04:26PM
9
Jul 28, 2020 04:54PM
1
Jul 28, 2020 05:23PM
6
Jul 28, 2020 07:30PM
3
Jul 28, 2020 07:56PM
4
Jul 31, 2020 09:44AM
2
Jul 31, 2020 01:31PM
3
Jul 31, 2020 01:49PM
2
Jul 31, 2020 06:14PM
2
Jul 31, 2020 06:16PM
3
Jul 31, 2020 06:33PM

Was the ACE2 one of the things that was measured in the New Zealand trial in Jan 2017. That was a single dose that apparently had shocking and highly encouraging results.

CALGARYJan. 23, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced preliminary results from the New Zealand based Phase 1 trial with severe kidney (renal) impaired patients. The data showed remarkable results in reducing inflamed protein biomarkers in patients with severe kidney impairment versus healthy control patients. It is believed that this is the first time in medical history that a direct connection of this type can be made between epigenetic regulation and its potential for positive disease impact. Both the healthy group and the severely impaired kidney group received equal amounts of apabetalone.

"It was shocking and highly encouraging to see the direct comparison of the protein data ranked by magnitude of effect in the two groups. For the first time, epigenetic and BET inhibition clinical data has been shown to differentially affect genes and proteins between advanced chronic kidney disease (CKD) patients and normal subjects," stated Donald McCaffrey, President and CEO.

tada

6
Aug 01, 2020 08:32AM
7
Aug 01, 2020 11:52AM
3
Aug 01, 2020 03:10PM
3
Aug 01, 2020 03:14PM
6
Aug 01, 2020 09:09PM
7
Aug 02, 2020 03:42PM
4
Aug 02, 2020 09:39PM
5
Aug 04, 2020 12:15AM
3
Aug 04, 2020 04:16AM
1
Aug 04, 2020 07:30AM
7
Aug 04, 2020 10:35AM
5
Sep 04, 2020 07:38PM
Share
New Message
Please login to post a reply